Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernanda Ludolf

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Cytokine|February 19, 2024
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasisCamila S Freitas, Isabela A G Pereira, Daniela P Lage, et al.
Cytokine|March 26, 2022
Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infectionDaniela P Lage, Amanda S Machado, Danniele L Vale, et al.
Cellular Immunology|August 23, 2020
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasisJoão A Oliveira-da-Silva, Amanda S Machado, Fernanda F Ramos, et al.
Vaccines|July 27, 2022
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against <i>Leishmania infantum</i> InfectionDaniela P Lage, Danniele L Vale, Flávia P Linhares, et al.
Microbial Pathogenesis|December 9, 2021
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteinsNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Experimental Parasitology|December 30, 2021
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary studyDébora V C Mendonça, Grasiele S V Tavares, Isabela A G Pereira, et al.
Experimental Parasitology|July 6, 2020
A new Leishmania hypothetical protein can be used for accurate serodiagnosis of canine and human visceral leishmaniasis and as a potential prognostic marker for human diseaseAmanda S Machado, Fernanda F Ramos, Thaís T O Santos, et al.
Microbial Pathogenesis|June 3, 2020
Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasisJoão A Oliveira-da-Silva, Amanda S Machado, Grasiele S V Tavares, et al.
Parasitology Research|October 19, 2021
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfectionNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Medical Microbiology and Immunology|April 19, 2021
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasisRafaella R Costa, João A Oliveira-da-Silva, Thiago A R Reis, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Cytokine|February 19, 2024
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasisCamila S Freitas, Isabela A G Pereira, Daniela P Lage, et al.
Cytokine|March 26, 2022
Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infectionDaniela P Lage, Amanda S Machado, Danniele L Vale, et al.
Cellular Immunology|August 23, 2020
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasisJoão A Oliveira-da-Silva, Amanda S Machado, Fernanda F Ramos, et al.
Vaccines|July 27, 2022
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against <i>Leishmania infantum</i> InfectionDaniela P Lage, Danniele L Vale, Flávia P Linhares, et al.
Microbial Pathogenesis|December 9, 2021
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteinsNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Experimental Parasitology|December 30, 2021
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary studyDébora V C Mendonça, Grasiele S V Tavares, Isabela A G Pereira, et al.
Experimental Parasitology|July 6, 2020
A new Leishmania hypothetical protein can be used for accurate serodiagnosis of canine and human visceral leishmaniasis and as a potential prognostic marker for human diseaseAmanda S Machado, Fernanda F Ramos, Thaís T O Santos, et al.
Microbial Pathogenesis|June 3, 2020
Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasisJoão A Oliveira-da-Silva, Amanda S Machado, Grasiele S V Tavares, et al.
Parasitology Research|October 19, 2021
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfectionNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Medical Microbiology and Immunology|April 19, 2021
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasisRafaella R Costa, João A Oliveira-da-Silva, Thiago A R Reis, et al.
Pageof 8